FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
58 letters match. Newest first.
-
DrugsNatural Essentials, Inc.
FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.
High risk -
DrugsLGM Pharma Solutions, LLC
FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.
High risk -
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsUCSF Radiopharmaceutical Facility
FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.
High risk -
DrugsMedical Products Laboratories, Inc.
Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.
High risk -
DrugsCohance Lifesciences Limited
Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.
High risk -
DrugsUnipack LLC
FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsScientific Protein Laboratories, LLC
FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.
High risk -
DrugsJanssen Vaccines Corp., A Johnson & Johnson Company
FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.
Medium -
DrugsSomerset Therapeutics Private Limited
FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
High risk -
DrugsAmneal Pharmaceuticals, LLC
FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.
High risk -
DrugsChromatography Institute of America dba Compounder’s International Analytical Laboratory
FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsShiva Analyticals Private Limited
FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.
High risk -
DrugsGlenmark Pharmaceuticals Limited
FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.
High risk -
DrugsCTK OTC Laboratories LLC formerly FMK LABS, Inc.
CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.
High risk -
DrugsNWL Netherlands Services B.V.
FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.
High risk -
DrugsExcelvision Fareva
Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharma
FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.
High risk -
DrugsChem-Tech, Ltd.
Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.
High risk -
DrugsSanofi
FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.
High risk -
DrugsZydus Lifesciences Limited
FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.
High risk -
DrugsEyePoint Pharmaceuticals, Inc.
FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.
High risk -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
DrugsLaboratorio Magnachem International
FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.
High risk -
DrugsSun Pharmaceutical Industries Limited
FDA cited Sun Pharmaceutical Industries for inadequate cleaning and maintenance at its Dadra drug plant, risking cross-contamination, and for weak investigations.
High risk -
DrugsWestwood Laboratories LLC
FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.
High risk -
DrugsSeatex, LLC
Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.
High risk -
DrugsNatco Pharma Limited
FDA warned Natco Pharma of adulterated drugs after finding dirty equipment and weak investigations at an India plant.
High risk -
DrugsCosmetic Specialty Labs, Inc.
FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.
High risk -
DrugsCipla Limited
FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.
High risk -
DrugsALI Pharmaceutical Manufacturing, LLC
FDA says ALI Pharmaceutical Manufacturing failed to validate and control its porcine thyroid drug substance process, making the drug substance adulterated.
High risk -
DrugsDenison Pharmaceuticals, LLC
Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.
High risk -
DrugsBaxter Healthcare Corporation
FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.
High risk -
DrugsMedgel Private Limited
FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.
High risk -
DrugsNeilMed Pharmaceuticals Inc.
FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.
High risk -
DrugsRemedyRepack, Inc.
RemedyRepack, a drug repackager in Indiana, Pennsylvania, failed CGMP, including cleaning and beta-lactam cross-contamination controls.
High risk -
DrugsAG Hair Limited
FDA warned AG Hair Limited over CGMP failures for hand sanitizer drugs, including inadequate investigations, microbiological controls, and component testing.
High risk -
DrugsLegacy Pharmaceutical Packaging LLC
Legacy Pharmaceutical Packaging, a drug repackager, was cited for CGMP violations and insanitary conditions after foreign tablets and floor-picked tablets were found.
High risk -
DrugsSterling Pharmaceutical Services, LLC
Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.
High risk